The Era of Janus Kinase Inhibitors for Inflammatory Bowel Disease Treatment

For a significant proportion of patients with inflammatory bowel disease (IBD), primary non-response and secondary loss of response to treatment remain significant issues. Anti-tumor necrosis factor therapies have been licensed for use in IBD. Other disease-related pathways have been targeted as wel...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Jin-Woo, Kim, Su-Young
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582842/
https://www.ncbi.nlm.nih.gov/pubmed/34768752
http://dx.doi.org/10.3390/ijms222111322

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582842/
https://www.ncbi.nlm.nih.gov/pubmed/34768752
http://dx.doi.org/10.3390/ijms222111322

Ejemplares similares